Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting

Schedule of certain segment information

	Year Ended December 31,
	2025		2024
Grant and award revenue	$	4,904	$	5,174
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		114		6,840
AP-PA02: Cystic Fibrosis		33		236
AP-SA02: Bacteremia		2,157		4,177
AP-SA02: Prosthetic Joint Infection		2		35
Expenses not allocated by projects		2,696		2,408
Total external research and development expenses		5,002		13,696
Research and development personnel expenses		9,199		10,764
Other research and development expenses		9,516		9,966
Total research and development expenses		23,717		34,426
General and administrative expenses:
General and administrative personnel expenses		4,897		4,935
Other general and administrative expenses		7,512		8,249
Total general and administrative expenses		12,409		13,184
Impairment expense		5,412		-
Total operating expenses		41,538		47,610
Operating loss		(36,634)		(42,436)
Other income (expense), net		(137,165)		23,520
Net loss	$	(173,799)	$	(18,916)